Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
Heart failure affects an estimated 64 million people worldwide and roughly six million in the United States alone. For patients whose condition stems from ischemic injury — where the heart muscle has been damaged by reduced blood flow — existing pharmaceutical treatments have meaningful but limited reach. A new dataset presented at the Technology and Heart Failure Therapeutics (THT) conference in Boston earlier this month suggests that for a defined subgroup of these patients, a therapy using their own bone marrow cells may be able to slow or arrest one of the most dangerous features of the disease: the progressive enlargement and weakening of the heart itself.
What BioCardia presented
BioCardia (Nasdaq: BCDA) reported late-breaking echocardiography results from its Phase III CardiAMP HF trial on March 3, with the data presented by Dr. Amish Raval of the University of Wisconsin School of Medicine as national co-principal investigator. The findings showed that patients receiving the CardiAMP autologous cell therapy demonstrated positive evidence of decreased pathological left ventricular remodeling compared to controls — in plainer terms, their hearts showed less of the adverse enlargement that typically marks disease progression in ischemic HFrEF.
The most compelling signal came from a prespecified subgroup: patients with elevated baseline NTproBNP levels, a biomarker of myocardial stress. In this group, the differences between treated and control patients in both left ventricular end-diastolic and end-systolic volumes were described as clinically meaningful and statistically significant, according to BioCardia’s press release. It should be noted that the primary endpoint of the CardiAMP HF trial focused on major adverse cardiac events and functional status; the imaging results are supportive findings rather than the trial’s primary measure of success. That said, for a field in which structural benefit has been notoriously difficult to demonstrate, data showing less adverse remodeling in the highest-risk patients bolster the case for a genuine biological effect rather than a statistical artefact.
The echocardiography analyses were conducted blind by the Yale University Cardiovascular Research Group, adding methodological credibility to the findings.
According to Wilson Tang of the Cleveland Clinic, a member of the executive steering committee for the CardiAMP HF trials, the NTproBNP-elevated subgroup showed less adverse cardiac remodeling per core-lab measurements. Carl Pepine of the University of Florida, co-national principal investigator, framed the broader context: the burden of heart failure continues to grow, cardiac ischemia dominates the cause, and the current pharmaceutical toolkit has limits.
The therapy itself
CardiAMP is an autologous cell therapy — it uses a patient’s own bone marrow cells rather than donor or manufactured biological material. Those cells are delivered directly to the site of cardiac dysfunction via a minimally invasive catheter-based procedure, with the aim of stimulating the body’s natural healing mechanisms, increasing capillary density, and reducing tissue fibrosis. The therapy holds FDA Breakthrough Device Designation. Clinical development has been supported by the Maryland Stem Cell Research Fund and is reimbursed by the Centers for Medicare and Medicaid Services under investigational use.
A critical design feature distinguishes CardiAMP from earlier cell therapy programs that failed to show consistent benefit in unselected populations. Rather than administering cells to all comers, BioCardia uses a proprietary cell potency assay to screen patients prior to enrollment, selecting only those whose bone marrow cells meet a threshold for biological activity. This patient selection methodology — not just the delivery system — may explain the positive signal seen here. Previous generations of cell therapy, including trials using unfractionated bone marrow cells and the now-discredited cardiac stem cell programs, largely failed because they treated heterogeneous populations without accounting for the variable regenerative capacity of individual patients’ cells.
The two-trial structure
Readers should note that BioCardia is running two distinct Phase III programs under the CardiAMP platform. The CardiAMP HF trial, whose echocardiography data were presented at THT, is the primary study from which the current findings derive. CardiAMP HF II is a separate, currently enrolling confirmatory trial, designed to support regulatory approval or label expansion. The two trials are complementary; the data presented this month come exclusively from the first.
Why the remodeling data matter
Reduced ventricular size in ischemic heart failure has long been recognized as highly prognostic for better long-term outcomes. A heart that stops enlarging — or begins to reverse its enlargement — is a heart under less mechanical strain, with better odds of sustained function. The echocardiography data reported at THT align with previously reported reductions in major adverse cardiovascular events and improvements in quality of life from the same trial, suggesting the structural signal is consistent with clinical benefit rather than an isolated imaging finding. The significance of the NTproBNP-elevated subgroup specifically is that it identifies patients with higher measurable myocardial stress — arguably those with the most to gain from an intervention targeting the underlying biology of remodeling.
The investor context
BioCardia is a small clinical-stage company with a market capitalization of approximately $12 million. As of its most recent quarterly filing, the company held $5.3 million in cash at the end of September 2025, providing runway into the second quarter of 2026. That timeline is immediate. With the CardiAMP HF II trial actively enrolling and a potential FDA submission on the horizon, the company will almost certainly need to raise capital in the near term. Given the current market cap, any such raise carries meaningful dilution risk for existing shareholders — a reality investors should weigh alongside the clinical data.
BioCardia has also initiated formal regulatory consultations with Japan’s PMDA, adding a potential non-US commercialization pathway that is worth monitoring but remains early stage.
The bigger picture
What the CardiAMP HF data add to the cardiovascular field is a meaningful contribution to a longer and often frustrating debate about whether cellular regenerative approaches can deliver durable, measurable benefit in heart failure. The ischemic HFrEF population — roughly half of all heart failure patients in Western registries — has better pharmaceutical options than it did a decade ago. But for patients inadequately served by guideline-directed medical therapy, the search for something that addresses structural damage rather than managing symptoms continues.
A therapy that helps the heart stop remodeling adversely, particularly in the patients most biologically compromised and selected specifically for their cells’ regenerative capacity, is the kind of signal the field has been searching for. Whether the full dataset, when published, confirms that picture at scale is the question that will define BioCardia’s near-term clinical and commercial future.